Member Registration July 28-30, 2017 Brochure Meeting Fees: $125 non-physician $225 physician Payments are to made to ACC. Click Here to make payments. The Grand Hotel Marriott, One Grand Boulevard, AL 36564 Hotel Reservations – Book Today! – Ph: 1-251-928-9201 … Continued
U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.
U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.